Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Core Scientific, Inc./txCORZ · Entity 389 | Director | February 04, 2026 | February 06, 2026 |
| Dave Inc./DEDAVE · Entity 4017 | Director | June 05, 2026 | June 09, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director | January 04, 2024 | January 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Core Scientific, Inc./tx
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 454,162 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 18,575 · Balance 454,162 F1: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date.
Dave Inc./DE
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy Family Foundation | 0 |
Reported balance
After 2026-06-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-05 · Gift · Disposed 2,200 · Balance 0 F1: Represents a bona fide gift to a charitable organization. |
| Class A Common StockSEC Table I · non-derivative | Direct | 75,834 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 75,834 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a bona fide gift to a charitable organization.
ORAMED PHARMACEUTICALS INC.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 155,320 |
Ending reported balance
After 2024-01-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-04 · Grant · Acquired 30,000 · Balance 146,500 F1: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Row 2 · 2024-01-04 · Grant · Acquired 8,820 · Balance 155,320 F2: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of 2,205 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F2: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of 2,205 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MIDWEST HOLDING INC.
Report date December 20, 2023 · Filed December 21, 2023
Section 16 reporting ended · disclosed 2023-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,164 |
Reported balance
After 2023-12-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-20 · Disposition to issuer · Disposed 22,661 · Balance 1,164 F1: The shares of Company common stock (the "Company Common Stock") were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 30, 2023 (the "Merger Agreement"), by and among Midwest Holding Inc., a Delaware corporation (the "Company"), Midas Parent, LP, a Delaware limited partnership ("Parent") and Midas Merger Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, whereby at the effective time of the merger contemplated therein (the "Effective Time"), each share of Company Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as provided in the Merger Agreement, was converted into the right to receive $27.00 in cash, without interest (the "Merger Consideration"), subject to any required tax withholding as provided in the Merger Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-20 · Disposition to issuer · Disposed 1,164 · Balance 0 F2: This number reflects the number of shares of Company Common Stock subject to outstanding restricted stock unit awards. F3: At the Effective Time, each restricted stock unit award for shares of Company Common Stock vested or held by the reporting person, as well as other non-employee directors or certain identified individuals (whether or not vested), and restricted stock unit award for shares of Company Common Stock that vested upon the merger under the terms applicable thereto, in each case, was cancelled and converted, in accordance with the terms of the Merger Agreement, into the right to receive a cash payment equal to, for each share of Common Stock subject to such award held by the reporting person immediately prior to the Effective Time, the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Company common stock (the "Company Common Stock") were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 30, 2023 (the "Merger Agreement"), by and among Midwest Holding Inc., a Delaware corporation (the "Company"), Midas Parent, LP, a Delaware limited partnership ("Parent") and Midas Merger Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, whereby at the effective time of the merger contemplated therein (the "Effective Time"), each share of Company Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as provided in the Merger Agreement, was converted into the right to receive $27.00 in cash, without interest (the "Merger Consideration"), subject to any required tax withholding as provided in the Merger Agreement.
F2: This number reflects the number of shares of Company Common Stock subject to outstanding restricted stock unit awards.
F3: At the Effective Time, each restricted stock unit award for shares of Company Common Stock vested or held by the reporting person, as well as other non-employee directors or certain identified individuals (whether or not vested), and restricted stock unit award for shares of Company Common Stock that vested upon the merger under the terms applicable thereto, in each case, was cancelled and converted, in accordance with the terms of the Merger Agreement, into the right to receive a cash payment equal to, for each share of Common Stock subject to such award held by the reporting person immediately prior to the Effective Time, the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 09:00 UTC | Dave Inc./DE DAVE · Entity 4017 | GiftClass A Common Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-263065 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Foundation Disclosed balance after: 0 F1 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 22:00 UTC | Dave Inc./DE DAVE · Entity 4017 | GrantClass A Common Stock | 637 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-257854 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,834 F1 · shares: Represents shares of Class A Common Stock underlying a restricted stock unit award ("RSU") granted under the Issuer's Amended and Restated 2021 Equity Incentive Plan in connection with annual awards to directors for service as a member of the Issuer's Board of Directors. The RSU will vest in full on the earlier of (i) June 2, 2027, and (ii) the date of the Issuer's next annual shareholder's meeting, subject to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:11 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 18,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000549 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,162 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 23:26 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GiftCommon Stock | 40,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000005 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,587 F1 · kind: Reflects a charitable donation. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:53 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseTranche 1 Warrants · Derivative | 30,000 | $9.95 Strike: $6.81 | $298,440.00 |
DisclosureSEC source: 0000905148-25-003928 · form4.xml · derivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-23 F2 · price: The price reported is a weighted average price. These Tranche 1 Warrants were purchased in multiple transactions at prices ranging from $9.85 to $10.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Tranche 1 Warrants purchased at each separate price within such range. F1 · derivative.exercise_date: Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $6.81 per share, subject to certain adjustments. Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:56 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 591 | $229.75 | $135,782.25 |
DisclosureSEC source: 0000950170-25-114621 · ownership.xml · nonDerivative · entry 5 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,197 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.39 to $230.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:56 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 822 | $228.64 | $187,942.08 |
DisclosureSEC source: 0000950170-25-114621 · ownership.xml · nonDerivative · entry 4 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,788 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.38 to $229.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:56 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 2,462 | $227.90 | $561,089.80 |
DisclosureSEC source: 0000950170-25-114621 · ownership.xml · nonDerivative · entry 3 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,610 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.36 to $228.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:56 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 848 | $226.80 | $192,326.40 |
DisclosureSEC source: 0000950170-25-114621 · ownership.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,072 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.35 to $227.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:56 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 3 | $225.21 | $675.63 |
DisclosureSEC source: 0000950170-25-114621 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,920 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 228 | $203.99 | $46,509.72 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 9 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,923 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.54 to $204.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 1,384 | $202.86 | $280,758.24 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 8 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,151 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.50 to $203.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 596 | $201.80 | $120,272.80 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 7 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,535 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.48 to $202.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 2,327 | $201.10 | $467,959.70 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 6 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,131 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.48 to $201.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 3,619 | $199.90 | $723,438.10 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 5 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,458 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.47 to $200.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 3,035 | $198.98 | $603,904.30 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 4 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,077 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.46 to $199.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 800 | $197.95 | $158,360.00 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 3 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,112 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.40 to $198.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 1,012 | $196.94 | $199,303.28 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,912 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.38 to $197.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:43 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 1,659 | $195.79 | $324,815.61 |
DisclosureSEC source: 0000950170-25-113312 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,924 F1 · kind: The sales reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.30 to $196.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:34 UTC | Dave Inc./DE DAVE · Entity 4017 | GiftClass A Common Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084877 · ownership.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Foundation Disclosed balance after: 2,200 F1 · shares: Represents a transfer of shares of Class A Common Stock for no consideration to a family foundation controlled by the Reporting Person. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:34 UTC | Dave Inc./DE DAVE · Entity 4017 | GiftClass A Common Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084877 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,583 F1 · shares: Represents a transfer of shares of Class A Common Stock for no consideration to a family foundation controlled by the Reporting Person. F2 · balance_after: Includes the grant of 1,105 restricted stock units as reported in the Reporting Person's Form 4 filed on June 6, 2025. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:34 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 100 | $207.79 | $20,779.00 |
DisclosureSEC source: 0000950170-25-082415 · ownership.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,678 F1 · shares: Represents a sale of shares of Class A Common Stock to satisfy tax obligations arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.78 to $207.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:34 UTC | Dave Inc./DE DAVE · Entity 4017 | SaleClass A Common Stock | 5,400 | $206.92 | $1,117,368.00 |
DisclosureSEC source: 0000950170-25-082415 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,778 F1 · shares: Represents a sale of shares of Class A Common Stock to satisfy tax obligations arising from the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.51 to $207.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 6, 2025 23:58 UTC | Dave Inc./DE DAVE · Entity 4017 | GrantClass A Common Stock | 1,105 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083385 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,283 F1 · shares: Represents shares of Class A Common Stock underlying a restricted stock unit award ("RSU") granted under the Issuer's Amended and Restated 2021 Equity Incentive Plan in connection with annual awards to directors for service as a member of the Issuer's Board of Directors. The RSU will vest in full on the earlier of (i) June 2, 2026, and (ii) the date of the Issuer's next annual shareholder's meeting, subject to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. F2 · balance_after: Does not reflect a subsequent sale of 5,500 shares of Class A Common Stock as reported in the Reporting Person's Form 4 filed on June 5, 2025. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:14 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 110,000 | $10.87 | $1,195,370.00 |
DisclosureSEC source: 0000905148-25-001941 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,687 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.83 to $10.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 00:12 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 20,448 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000232 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,687 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on January 27, 2026, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 23:51 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 105,000 | $18.11 | $1,901,949.00 |
DisclosureSEC source: 0000905148-24-003266 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,239 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 23:51 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | OtherTranche 2 Warrants · Derivative | 195,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000905148-24-003021 · form4.xml · derivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of the Issuer's common stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days, subject to certain adjustments. The Tranche 2 Warrants became exercisable at the option of the registered holders on July 11, 2024. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 23:51 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | OtherCommon Stock | 195,000 | $0.01 | $1,950.00 |
DisclosureSEC source: 0000905148-24-003021 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,239 Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:34 UTC | Dave Inc./DE DAVE · Entity 4017 | GrantClass A Common Stock | 4,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000950172-24-000328 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,178 F1 · shares: Represents shares of Class A Common Stock underlying a restricted stock unit award ("RSU") granted under the Issuer's Amended and Restated 2021 Equity Incentive Plan in connection with annual awards to directors for service as a member of the Issuer's Board of Directors. The RSU will vest in full on the earlier of (i) June 3, 2025, and (ii) the date of the Issuer's next annual shareholder's meeting, subject to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. Read SEC document |
| May 27, 2024 Filed May 29, 2024 00:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 47,793 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001643 · form4.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,239 F2 · shares: Represents an RSU grant. The RSUs will vest in full on January 23, 2025, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| May 27, 2024 Filed May 29, 2024 00:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 127,446 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001643 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,446 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on January 23, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:02 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseTranche 2 Warrants · Derivative | 105,000 | $2.52 Strike: $0.01 | $264,684.00 |
DisclosureSEC source: 0000905148-24-001417 · form4.xml · derivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 105,000 shares Expires 2029-01-23 F2 · price: The price reported is a weighted average price. These Tranche 2 Warrants were purchased in multiple transactions at prices ranging from $2.48 to $2.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Tranche 2 Warrants purchased at each separate price within such range. F1 · derivative.exercise_date: Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of the Issuer's common stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days, subject to certain adjustments. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:45 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseTranche 2 Warrants · Derivative | 90,000 | $2.15 Strike: $0.01 | $193,788.00 |
DisclosureSEC source: 0000905148-24-000971 · form4.xml · derivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-23 F3 · price: The price reported is a weighted average price. These Tranche 2 Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Tranche 2 Warrants purchased at each separate price within such range. F2 · derivative.exercise_date: Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of the Issuer's common stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days, subject to certain adjustments. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:45 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 80,000 | $3.07 | $245,968.00 |
DisclosureSEC source: 0000905148-24-000971 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.99 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within such range. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:03 UTC | Dave Inc./DE DAVE · Entity 4017 | PurchaseClass A Common Stock | 800 | $37.31 | $29,848.00 |
DisclosureSEC source: 0001096906-24-000381 · form4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,452 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.21 to $37.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:36 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 8,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001141 · doc4.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,320 F2 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of 2,205 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:36 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001141 · doc4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,500 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:07 UTC | MIDWEST HOLDING INC. MDWT · Entity 95904 | Disposition to issuerCommon Stock | 1,164 | $27.00 | $31,428.00 |
DisclosureSEC source: 0001104659-23-128205 · tm2333048-5_4seq1.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: This number reflects the number of shares of Company Common Stock subject to outstanding restricted stock unit awards. F3 · kind: At the Effective Time, each restricted stock unit award for shares of Company Common Stock vested or held by the reporting person, as well as other non-employee directors or certain identified individuals (whether or not vested), and restricted stock unit award for shares of Company Common Stock that vested upon the merger under the terms applicable thereto, in each case, was cancelled and converted, in accordance with the terms of the Merger Agreement, into the right to receive a cash payment equal to, for each share of Common Stock subject to such award held by the reporting person immediately prior to the Effective Time, the Merger Consideration. F3 · price: At the Effective Time, each restricted stock unit award for shares of Company Common Stock vested or held by the reporting person, as well as other non-employee directors or certain identified individuals (whether or not vested), and restricted stock unit award for shares of Company Common Stock that vested upon the merger under the terms applicable thereto, in each case, was cancelled and converted, in accordance with the terms of the Merger Agreement, into the right to receive a cash payment equal to, for each share of Common Stock subject to such award held by the reporting person immediately prior to the Effective Time, the Merger Consideration. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:07 UTC | MIDWEST HOLDING INC. MDWT · Entity 95904 | Disposition to issuerCommon Stock | 22,661 | $27.00 | $611,847.00 |
DisclosureSEC source: 0001104659-23-128205 · tm2333048-5_4seq1.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,164 F1 · kind: The shares of Company common stock (the "Company Common Stock") were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 30, 2023 (the "Merger Agreement"), by and among Midwest Holding Inc., a Delaware corporation (the "Company"), Midas Parent, LP, a Delaware limited partnership ("Parent") and Midas Merger Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, whereby at the effective time of the merger contemplated therein (the "Effective Time"), each share of Company Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as provided in the Merger Agreement, was converted into the right to receive $27.00 in cash, without interest (the "Merger Consideration"), subject to any required tax withholding as provided in the Merger Agreement. F1 · price: The shares of Company common stock (the "Company Common Stock") were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 30, 2023 (the "Merger Agreement"), by and among Midwest Holding Inc., a Delaware corporation (the "Company"), Midas Parent, LP, a Delaware limited partnership ("Parent") and Midas Merger Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, whereby at the effective time of the merger contemplated therein (the "Effective Time"), each share of Company Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as provided in the Merger Agreement, was converted into the right to receive $27.00 in cash, without interest (the "Merger Consideration"), subject to any required tax withholding as provided in the Merger Agreement. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 00:35 UTC | Dave Inc./DE DAVE · Entity 4017 | PurchaseClass A Common Stock | 12,941 | $6.40 | $82,760.28 |
DisclosureSEC source: 0001209191-23-057680 · doc4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,652 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.3078 to $6.4998, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2023 Filed Jul 10, 2023 22:13 UTC | Dave Inc./DE DAVE · Entity 4017 | GrantClass A Common Stock | 30,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041962 · doc4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,711 F1 · shares: Represents shares of Class A Common Stock underlying a restricted stock unit award ("RSU") granted under the Issuer's 2021 Equity Incentive Plan. The RSU will vest in three equal annual installments beginning on the earlier to occur of (i) the next annual meeting of stockholders of the Issuer or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 13:26 UTC | MIDWEST HOLDING INC. mdwt · Entity 95904 | GrantCommon Stock | 1,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001921268-23-000003 · primary_doc.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,825 F1 · price: The reported shares underlie a restricted stock unit award which vests on the earlier of the first anniversary of its date of grant and the next date of the annual meeting of stockholders, subject the terms of the restricted stock unit agreement and the Issuer's Long-Term Incentive Plan which includes acceleration of vesting under certain circumstances. Each restricted stock unit represents the contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 10:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024938 · doc4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,500 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 2,500 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 50,000 | $2.05 | $102,450.00 |
DisclosureSEC source: 0001209191-23-018944 · doc4.xml · nonDerivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,500 F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 20,000 | $1.96 | $39,120.00 |
DisclosureSEC source: 0001209191-23-018944 · doc4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $1.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:01 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043772 · doc4.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 4,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:07 UTC | MIDWEST HOLDING INC. mdwt · Entity 95904 | GrantVoting Common Stock | 2,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001921268-22-000006 · primary_doc.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,661 F1 · price: The reported shares underlie a restricted stock unit award which vests on the earlier of the first anniversary of its date of grant and the next date of the annual meeting of stockholders, subject to the terms of the restricted stock unit agreement and the Issuer's Long-Term Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001213900-22-023728 · ownership.xml · derivative · entry 2 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-05-02 F2 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 1,875 shall vest on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 4,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-023728 · ownership.xml · nonDerivative · entry 1 Rozov Yadin · CIK 0001921268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,125 shall vest on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.